Lilly's CYRAMZA (ramucirumab) significantly improved overall survival in phase 3 non-small cell lung cancer study. Results from the REVEL trial were published in The Lancet and also presented at ASCO ...
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...
Eli Lilly (NYSE:LLY) announced on Wednesday that its FDA-approved antitumor agent Verzenio, as part of a combination regimen, improved overall survival in a late-stage trial for certain patients with ...
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback